Biosimilars Market, 2012 to 2023

Date: January 23, 2018
Pages: 192
Price:
US$ 4,400.00
Publisher: Precision Business Insights (PBI)
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B3201109C7DEN
Leaflet:

Download PDF Leaflet

Biosimilars Market, 2012 to 2023
Biosimilars Market: By-Drug Class (Monoclonal Antibodies, Recombinant Hormones, Recombinant Growth Factors, Immunomodulators, Anti-Inflammatory Agents, and Others), By Application (Oncology, Blood Disorders, Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Diabetes, and Others), By Manufacturing Type (Captive and Out-sourcing), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Global Biosimilars Market Report Description:

Global biosimilars market report gives a comprehensive outlook on biosimilars products across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on biosimilars market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application, manufacturing type, distribution channel, and geographic regions. This report studies biosimilars market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, biosimilars market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed biosimilars market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the biosimilars market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescription of biosimilar products.

Global Biosimilars Market:

Global biosimilars market estimated to be valued US$ 4.10 Bn in 2017 and poised to grow at CAGR of 23.0% over 2017-2023. A market for biosimilars projected to reach US$ 14.23 Bn by 2023 owing to increasing patent expires of biologics and rising biosimilars product pipeline.

Growing demand for cost-effective medications to reduce healthcare burden is driving the market revenue growth

Global biosimilars market is gaining traction in recent times owing to its cost-effective pricing in comparison with patented or branded biologics, which are generally priced higher than biologics. The adoption of cost-effective biosimilars is rising in different healthcare setups across the developed and developing countries to curtail the growing pressure on healthcare budgets. The introduction of biosimilars has even led to improved access to the premium-priced biopharmaceuticals in developing and underdeveloped markets with lesser costs. Moreover, favourable government policies to promote cost-effective biosimilars expected to drive market revenue growth over the forecast period.

Increasing prevalence of several chronic diseases are expected to drive biosimilars market revenue growth over the forecast period

The rising prevalence of several chronic diseases such as cancer, diabetes, cardiovascular diseases, autoimmune disease, and among others across the developed and developing economies expected to drive the market for Biosimilars Market over the forecast period. The growing demand from developing and an underdeveloped market for improved healthcare access are driving the market revenue growth over the forecast period. Moreover, several players are increasing their focus from developed markets to developing markets to tap increasingly growing market opportunity is driving the market revenue growth. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide.

Europe emerged as prominent region for Biosimilars market across the globe

Europe market expected to hold the higher revenue share in global biosimilars market owing to healthcare practitioners shift to low priced drugs, and wider treatment choices available in the region. Asia-pacific biosimilars market projected to grow at highest CAGR over the forecast period in comparison with other regions owing to large out-of-pocket healthcare expenditure and large medical unmet need due to lack of patented product availability.

Competition Assessment

Key players profiled in the global Biosimilars market include:

Amgen Inc. (U.S.)
Biocon Ltd. (India)
Celltrion, Inc. (South Korea)
Dr Reddy’s Laboratories Ltd. (India)
F. Hoffmann-La Roche Ltd. (Switzerland)
Pfizer Inc. (U.S.)
Samsung Bioepis (South Korea)
Novartis AG (Switzerland)
Teva Pharmaceuticals Industries Ltd. (Israel)

Players in biosimilars market are focusing on introducing low-cost biosimilars in developed and developing economies to garner larger market revenue share in global biosimilars market. For instance, in 2015 Sandoz (Novartis AG) launched generic version (Glatopa) of copaxone (glatiramer acetate) in U.S. market.
1. EXECUTIVE SUMMARY

2. GLOBAL BIOSIMILARS MARKET INTRODUCTION

2.1. Global Biosimilars Market – Taxonomy
2.2. Global Biosimilars Market –Definitions
  2.2.1. Drug Class
  2.2.2. Application
  2.2.3. Manufacturing Type
  2.2.4. Distribution Channel

3. GLOBAL BIOSIMILARS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Biosimilars Market Dynamics – Factors Impact Analysis
3.6. Global Biosimilars Market – Regulations
  3.6.1. U.S.
  3.6.2. Europe

4. GLOBAL BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL BIOSIMILARS MARKET , BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Monoclonal Antibodies
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Recombinant Hormones
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Recombinant Growth Factors
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Immunomodulators
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Anti-Inflammatory Agents
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Others
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis

6. GLOBAL BIOSIMILARS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Oncology
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Blood Disorders
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Autoimmune Diseases
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Growth Hormone Deficiency
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis
6.5. Infectious Diseases
  6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.5.3. Market Opportunity Analysis
6.6. Diabetes
  6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.6.3. Market Opportunity Analysis
6.7. Others
  6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.7.3. Market Opportunity Analysis

7. GLOBAL BIOSIMILARS MARKET FORECAST, BY MANUFACTURING TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Captive
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Out-sourcing
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis

8. GLOBAL BIOSIMILARS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospital Pharmacies
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis

9. GLOBAL BIOSIMILARS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.5.3. Market Opportunity Analysis
9.6. Global Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Region, 2017 – 2023

10. NORTH AMERICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Monoclonal Antibodies
  10.1.2. Recombinant Hormones
  10.1.3. Recombinant Growth Factors
  10.1.4. Immunomodulators
  10.1.5. Anti-Inflammatory Agents
  10.1.6. Others
10.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Oncology
  10.2.2. Blood Disorders
  10.2.3. Autoimmune Diseases
  10.2.4. Growth Hormone Deficiency
  10.2.5. Infectious Diseases
  10.2.6. Diabetes
  10.2.7. Others
10.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Captive
  10.3.2. Out-sourcing
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Hospital Pharmacies
  10.4.2. Retail Pharmacies
  10.4.3. Online Pharmacies
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  10.5.1. U.S.
  10.5.2. Canada
10.6. North America Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
10.7. North America Biosimilars Market Dynamics – Trends

11. EUROPE BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Monoclonal Antibodies
  11.1.2. Recombinant Hormones
  11.1.3. Recombinant Growth Factors
  11.1.4. Immunomodulators
  11.1.5. Anti-Inflammatory Agents
  11.1.6. Others
11.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Oncology
  11.2.2. Blood Disorders
  11.2.3. Autoimmune Diseases
  11.2.4. Growth Hormone Deficiency
  11.2.5. Infectious Diseases
  11.2.6. Diabetes
  11.2.7. Others
11.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Captive
  11.3.2. Out-sourcing
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.4.1. Hospital Pharmacies
  11.4.2. Retail Pharmacies
  11.4.3. Online Pharmacies
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.5.1. Germany
  11.5.2. UK
  11.5.3. France
  11.5.4. Spain
  11.5.5. Italy
  11.5.6. Russia
  11.5.7. Poland
  11.5.8. Rest of Europe
11.6. Europe Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
11.7. Europe Biosimilars Market Dynamics – Trends

12. ASIA-PACIFIC BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Monoclonal Antibodies
  12.1.2. Recombinant Hormones
  12.1.3. Recombinant Growth Factors
  12.1.4. Immunomodulators
  12.1.5. Anti-Inflammatory Agents
  12.1.6. Others
12.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Oncology
  12.2.2. Blood Disorders
  12.2.3. Autoimmune Diseases
  12.2.4. Growth Hormone Deficiency
  12.2.5. Infectious Diseases
  12.2.6. Diabetes
  12.2.7. Others
12.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.3.1. Captive
  12.3.2. Out-sourcing
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Hospital Pharmacies
  12.4.2. Retail Pharmacies
  12.4.3. Online Pharmacies
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  12.5.1. Japan
  12.5.2. China
  12.5.3. India
  12.5.4. ASEAN
  12.5.5. Australia & New Zealand
  12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
12.7. Asia- Pacific Biosimilars Market Dynamics – Trends

13. LATIN AMERICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Monoclonal Antibodies
  13.1.2. Recombinant Hormones
  13.1.3. Recombinant Growth Factors
  13.1.4. Immunomodulators
  13.1.5. Anti-Inflammatory Agents
  13.1.6. Others
13.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.2.1. Oncology
  13.2.2. Blood Disorders
  13.2.3. Autoimmune Diseases
  13.2.4. Growth Hormone Deficiency
  13.2.5. Infectious Diseases
  13.2.6. Diabetes
  13.2.7. Others
13.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.3.1. Captive
  13.3.2. Out-sourcing
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.4.1. Hospital Pharmacies
  13.4.2. Retail Pharmacies
  13.4.3. Online Pharmacies
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.5.1. Brazil
  13.5.2. Mexico
  13.5.3. Argentina
  13.5.4. Venezuela
  13.5.5. Rest of Latin America
13.6. Latin America Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
13.7. Latin America Biosimilars Market Dynamics – Trends

14. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

14.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  14.1.1. Monoclonal Antibodies
  14.1.2. Recombinant Hormones
  14.1.3. Recombinant Growth Factors
  14.1.4. Immunomodulators
  14.1.5. Anti-Inflammatory Agents
  14.1.6. Others
14.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.2.1. Oncology
  14.2.2. Blood Disorders
  14.2.3. Autoimmune Diseases
  14.2.4. Growth Hormone Deficiency
  14.2.5. Infectious Diseases
  14.2.6. Diabetes
  14.2.7. Others
14.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.3.1. Captive
  14.3.2. Out-sourcing
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.4.1. Hospital Pharmacies
  14.4.2. Retail Pharmacies
  14.4.3. Online Pharmacies
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  14.5.1. Gulf Cooperation Council (GCC) Countries
  14.5.2. Israel
  14.5.3. South Africa
  14.5.4. Rest of MEA
14.6. MEA Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
14.7. MEA Biosimilars Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. Amgen Inc. (U.S.)
  15.2.2. Biocon Ltd. (India)
  15.2.3. Celltrion, Inc. (South Korea)
  15.2.4. Dr Reddy’s Laboratories Ltd. (India)
  15.2.5. F. Hoffmann-La Roche Ltd. (Switzerland)
  15.2.6. Pfizer Inc. (U.S.)
  15.2.7. Samsung Bioepis (South Korea)
  15.2.8. Novartis AG (Switzerland)
  15.2.9. Teva Pharmaceuticals Industries Ltd. (Israel)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS
Skip to top


Ask Your Question

Biosimilars Market, 2012 to 2023
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: